The filing confirms a third recurring commercial shipment, but with zero revenue disclosed and a $13M market cap, the stock has historically sold off 5-16% on similar news. Monitor for actual revenue disclosure in the next quarterly filing (10-Q or 20-F) to validate whether commercial scale is material. Until then, treat as a non-material operational update.
Price Chart
Executive Summary
Optimi Health announced its third commercial psilocybin export to Australia — a shipment of 1,000 capsules for treatment-resistant depression — marking continued commercial revenue generation but no financial figures were disclosed. The filing is operationally positive (third recurring shipment, expanding reimbursement, no serious adverse events reported) but lacks any revenue, earnings, or quantitative business data, limiting materiality for a $13M market cap stock.
Key Facts
- Third commercial export of 5mg psilocybin capsules to Australia since product launch in September 2025
- Shipment consisted of 1,000 capsules for treatment-resistant depression under Australia's Authorized Prescriber Scheme
- Reimbursement coverage expanding from both public and private payers, including Dept. of Veterans Affairs, NDIS, WorkCover, and Medibank
- More than 750 clinicians trained to deliver the therapy; no serious adverse events reported through Dec 31, 2025
- Product manufactured in-house at GMP facility in Princeton, BC under Health Canada license
- No financial figures (revenue, shipment value, cost, or earnings) disclosed in the filing
Financial Impact
No dollar amounts disclosed. Third commercial shipment of 1,000 capsules — revenue contribution is likely modest for a $13M market cap company, but recurring orders suggest nascent commercial traction.
Risk Factors
- No financial data provided — shipment size (1,000 capsules) suggests very low absolute revenue contribution
- Dependence on Australia's Authorized Prescriber Scheme regulatory framework, which could change
- Forward-looking statements about expanding reimbursement and recurring orders are not guaranteed
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001193125-26-286955 |
| Document: d145470d6k.htm | 0001193125-26-286955 |
| Document: 0001193125-26-286955-index-headers.html | 0001193125-26-286955 |
| Document: 0001193125-26-286955-index.html | 0001193125-26-286955 |
| Document: 0001193125-26-286955.txt | 0001193125-26-286955 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 26, 2026 today | 6-K | $3.36 | awaiting T+5 | — | $3.12 (−7.14%) |
Oct 20, 2026 6d ago | 6-K | $3.36 | awaiting T+5 | — | $3.12 (−7.14%) |
Oct 7, 2026 19d ago | 6-K | $4.04 $3.17 | ▼ −21.66% | ▼ −20.68% | $3.12 (−22.77%) |
Oct 5, 2026 21d ago | SC 13G/A | $4.13 $3.50 | ▼ −15.25% | ▼ −15.12% | $3.12 (−24.46%) |
Sep 29, 2026 27d ago | 6-K | $4.78 $4.13 | ▼ −13.60% | ▼ −15.55% | $3.12 (−34.73%) |
Sep 23, 2026 4w ago | 6-K | $4.96 $4.71 | ▼ −5.04% | ▼ −4.37% | $3.12 (−37.10%) |
Sep 22, 2026 4w ago | 6-K | $4.96 $4.78 | ▼ −3.63% | ▼ −2.44% | $3.12 (−37.10%) |
Sep 16, 2026 5w ago | 6-K | $4.90 $4.96 | ▲ +1.22% | ▼ −0.60% | $3.12 (−36.33%) |
Sep 10, 2026 6w ago | 6-K | $4.50 $4.96 | ▲ +10.22% | ▲ +10.72% | $3.12 (−30.67%) |
Aug 26, 2026 8w ago | 6-K | $4.89 $4.70 | ▲ +3.89% | ▲ +4.15% | $3.12 (+36.20%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers